Literature DB >> 25221935

Feasibility and validity of the pediatric ulcerative colitis activity index in routine clinical practice.

Jennifer L Dotson1, Wallace V Crandall, Peixin Zhang, Christopher B Forrest, L Charles Bailey, Richard B Colletti, Michael D Kappelman.   

Abstract

OBJECTIVES: The Pediatric Ulcerative Colitis Activity Index (PUCAI) is a noninvasive disease activity index developed as a clinical trial endpoint. More recently, practice guidelines have recommended the use of PUCAI in routine clinical care. We therefore sought to evaluate the feasibility, validity, and responsiveness of PUCAI in a large, diverse collection of pediatric gastroenterology practices.
METHODS: We extracted data from the 2 most recent encounters for patients with ulcerative colitis in the ImproveCareNow registry. Feasibility was determined by the percentage of patients for whom all PUCAI components were recorded, validity by correlation of PUCAI scores across physician global assessment (PGA) categories, and responsiveness to change by the correlation between the change in PUCAI and PGA scores between visits.
RESULTS: A total of 2503 patients were included (49.5% boys, age 15.2 ± 4.1 years, disease duration 3.7 ± 3.2 years). All items in the PUCAI were completed for 96% of visits. PUCAI demonstrated excellent discriminatory ability between remission, mild, and moderate disease; discrimination between moderate and severe disease was less robust. There was good correlation with PGA (r = 0.76 [P < 0.001] and weighted kappa κ = 0.73 [P < 0.001]). The PUCAI change scores correlated well with PGA change scores (P < 0.001). Test-retest reliability of the PUCAI was good (intraclass correlation coefficient 0.72 [95% confidence interval 0.70-0.75], P < 0.001). Guyatt responsiveness statistic was 1.18, and the correlation of ΔPUCAI with ΔPGA was 0.69 (P < 0.001).
CONCLUSIONS: The PUCAI is feasible to use in routine clinical settings. Evidence of its validity and responsiveness supports its use as a clinical tool for monitoring disease activity for patients with ulcerative colitis.

Entities:  

Mesh:

Year:  2015        PMID: 25221935      PMCID: PMC4308561          DOI: 10.1097/MPG.0000000000000568

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  19 in total

Review 1.  Methods for assessing responsiveness: a critical review and recommendations.

Authors:  J A Husted; R J Cook; V T Farewell; D D Gladman
Journal:  J Clin Epidemiol       Date:  2000-05       Impact factor: 6.437

2.  Outcomes and adverse events in children and young adults undergoing tacrolimus therapy for steroid-refractory colitis.

Authors:  Sheree Watson; Licia Pensabene; Paul Mitchell; Athos Bousvaros
Journal:  Inflamm Bowel Dis       Date:  2010-08-18       Impact factor: 5.325

Review 3.  Acute severe ulcerative colitis in children: a systematic review.

Authors:  Dan Turner; Anne M Griffiths
Journal:  Inflamm Bowel Dis       Date:  2011-01       Impact factor: 5.325

4.  Using the entire cohort in the receiver operating characteristic analysis maximizes precision of the minimal important difference.

Authors:  Dan Turner; Holger J Schünemann; Lauren E Griffith; Dorcas E Beaton; Anne M Griffiths; Jeffrey N Critch; Gordon H Guyatt
Journal:  J Clin Epidemiol       Date:  2008-11-14       Impact factor: 6.437

Review 5.  Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN.

Authors:  Dan Turner; Simon P L Travis; Anne M Griffiths; Frank M Ruemmele; Arie Levine; Eric I Benchimol; Marla Dubinsky; George Alex; Robert N Baldassano; Jacob C Langer; Robert Shamberger; Jeffrey S Hyams; Salvatore Cucchiara; Athos Bousvaros; Johanna C Escher; James Markowitz; David C Wilson; Gert van Assche; Richard K Russell
Journal:  Am J Gastroenterol       Date:  2011-01-11       Impact factor: 10.864

6.  Measuring change over time: assessing the usefulness of evaluative instruments.

Authors:  G Guyatt; S Walter; G Norman
Journal:  J Chronic Dis       Date:  1987

7.  Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study.

Authors:  Dan Turner; Anthony R Otley; David Mack; Jeffrey Hyams; J de Bruijne; Krista Uusoue; Thomas D Walters; Mary Zachos; Petar Mamula; Dorcas E Beaton; A Hillary Steinhart; Anne M Griffiths
Journal:  Gastroenterology       Date:  2007-05-21       Impact factor: 22.682

8.  Appraisal of the pediatric ulcerative colitis activity index (PUCAI).

Authors:  Dan Turner; Jeffrey Hyams; James Markowitz; Trudy Lerer; David R Mack; Jonathan Evans; Marian Pfefferkorn; Joel Rosh; Marsha Kay; Wallace Crandall; David Keljo; Anthony R Otley; Subra Kugathasan; Ryan Carvalho; Maria Oliva-Hemker; Christine Langton; Petar Mamula; Athos Bousvaros; Neal LeLeiko; Anne M Griffiths
Journal:  Inflamm Bowel Dis       Date:  2009-08       Impact factor: 5.325

9.  Responsiveness and validity in health status measurement: a clarification.

Authors:  G H Guyatt; R A Deyo; M Charlson; M N Levine; A Mitchell
Journal:  J Clin Epidemiol       Date:  1989       Impact factor: 6.437

10.  Pediatric modification of the Montreal classification for inflammatory bowel disease: the Paris classification.

Authors:  Arie Levine; Anne Griffiths; James Markowitz; David C Wilson; Dan Turner; Richard K Russell; John Fell; Frank M Ruemmele; Thomas Walters; Mary Sherlock; Marla Dubinsky; Jeffrey S Hyams
Journal:  Inflamm Bowel Dis       Date:  2010-11-08       Impact factor: 5.325

View more
  6 in total

1.  Longitudinal Patterns of Medication Nonadherence and Associated Health Care Costs.

Authors:  Kevin A Hommel; Meghan E McGrady; James Peugh; George Zacur; Katherine Loreaux; Shehzad Saeed; Elizabeth Williams; Lee A Denson
Journal:  Inflamm Bowel Dis       Date:  2017-09       Impact factor: 5.325

2.  Enhanced Contribution of HLA in Pediatric Onset Ulcerative Colitis.

Authors:  Suresh Venkateswaran; Jarod Prince; David J Cutler; Urko M Marigorta; David T Okou; Sampath Prahalad; David Mack; Brendan Boyle; Thomas Walters; Anne Griffiths; Cary G Sauer; Neal LeLeiko; David Keljo; James Markowitz; Susan S Baker; Joel Rosh; Marian Pfefferkorn; Melvin B Heyman; Ashish Patel; Anthony Otley; Robert Baldassano; Joshua Noe; Paul Rufo; Maria Oliva-Hemker; Sonia Davis; Michael E Zwick; Greg Gibson; Lee A Denson; Jeffrey Hyams; Subra Kugathasan
Journal:  Inflamm Bowel Dis       Date:  2018-03-19       Impact factor: 5.325

3.  Relations between disease status and body composition in pediatric inflammatory bowel disease.

Authors:  Saurabh Talathi; Pooja Nagaraj; Traci Jester; Jeanine Maclin; Taylor Knight; Margaux J Barnes
Journal:  Eur J Pediatr       Date:  2020-03-23       Impact factor: 3.183

4.  Validity and Responsiveness of the Patient-reported Outcomes Measurement Information System in Children With Ulcerative Colitis.

Authors:  Erica J Brenner; Millie D Long; Courtney M Mann; Li Lin; Wenli Chen; Camila Reyes; Kirsten M Bahnson; Bryce B Reeve; Michael D Kappelman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2021-07-01       Impact factor: 3.288

5.  Altered pattern of tumor necrosis factor-alpha production in peripheral blood monocytes from Crohn's disease.

Authors:  Claudia Loganes; Alessia Pin; Samuele Naviglio; Martina Girardelli; Anna Monica Bianco; Stefano Martelossi; Alberto Tommasini; Elisa Piscianz
Journal:  World J Gastroenterol       Date:  2016-11-07       Impact factor: 5.742

6.  Expression profile of the matricellular protein periostin in paediatric inflammatory bowel disease.

Authors:  Tracy Coelho; Eva Sonnenberg-Riethmacher; Yifang Gao; Enrico Mossotto; Alisher Khojanazarov; Annie Griffin; Saida Mukanova; Aiymkul Ashimkhanova; Rachel Haggarty; Anton Borissenko; James J Ashton; Imogen S Stafford; Akshay Batra; Nadeem A Afzal; Michael P Stanton; Bhumita Vadgama; Kapura Adrisova; Robert M Beattie; Anthony P Williams; Sarah Ennis; Dieter Riethmacher
Journal:  Sci Rep       Date:  2021-03-18       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.